ACUTE CHANGES IN THYROID VOLUME AND FUNCTION FOLLOWING I-131 THERAPY OF MULTINODULAR GOITER

被引:53
作者
NYGAARD, B
FABER, J
HEGEDUS, L
机构
[1] HERLEV UNIV HOSP,DEPT CLIN CHEM & ULTRASOUND,DK-2730 HERLEV,DENMARK
[2] FREDERIKSBERG UNIV HOSP,DEPT ENDOCRINOL E,FREDERIKSBERG,DENMARK
[3] ODENSE UNIV HOSP,DEPT ENDOCRINOL M,DK-5000 ODENSE,DENMARK
关键词
D O I
10.1111/j.1365-2265.1994.tb02784.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Many textbooks claim that radioiodine (I-131) treatment should be given with care to a goitre with substernal extension, for fear of acute swelling of the gland and thus respiratory problems. Since I-131 is used increasingly in the treatment of non-toxic as well as toxic goitre we have evaluated the acute changes in thyroid volume following I-131 therapy. DESIGN Evaluation of potential acute changes In thyroid volume and function after I-131 treatment in patients with non-toxic goitre treated because of compression symptoms or for cosmetic reasons, as well as in patients with toxic goitre. PATIENTS Out-patients with multinodular goitre, either non-toxic (n=20) or toxic (n=10). Excluded were patients with a substernal goitre. MEASUREMENTS Ultrasonically determined thyroid volume and standard thyroid function variables were investigated before and 2, 7, 14, 21, 28 and 35 days after treatment. RESULTS in non-toxic goitres the thyroid volume did not increase significantly, the maximum increase in the median volume being 4% on day 7. Serum levels of free T3 and free T4 indices increased by 20% (day 7) and 13% (day 14) (P = 0.002), respectively. Likewise thyroid volume in toxic nodular goitre did not change significantly after I-131 treatment (maximum median increase was 2%). None of the patients presented symptoms of tracheal compression. CONCLUSIONS I-131 treatment of non-toxic as well as toxic multinodular goitre does not seem to increase thyroid volume.
引用
收藏
页码:715 / 718
页数:4
相关论文
共 50 条
[21]   I-131 therapy, Graves' disease, multinodular goiter and toxic adenoma: Fixed activity versus calculated dose. [J].
Dehaes, B ;
Kiebooms, L ;
Drieskens, L ;
Tits, J ;
Parthoens, Y .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09) :994-994
[22]   THYROID DESTRUCTION BY I-131, AND REPLACEMENT THERAPY [J].
WINCHESTER, CF ;
COMAR, CL ;
DAVIS, GK .
SCIENCE, 1949, 110 (2856) :302-304
[23]   DECREASE OF THYROID VOLUME AFTER I-131 THERAPY FOR GRAVES-DISEASE [J].
REINERS, C ;
PETERS, H ;
FISCHER, C ;
SCHLEUSENER, H .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1992, 19 (08) :683-683
[24]   LONG-TERM FOLLOW-UP OF I-131 TREATED HYPERTHYROID MULTINODULAR GOITER [J].
ALJANADI, M ;
HART, IR .
CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1987, 10 (04) :B73-B73
[25]   THERAPY OF SOLITARY NODULE IN THYROID WITH I-131 [J].
MAGALOTTI, MF ;
BECKER, RJ ;
HUMMON, IF .
JOURNAL OF NUCLEAR MEDICINE, 1964, 5 (05) :357-357
[26]   HEMATOLOGIC CHANGES OBSERVED FOLLOWING I-131 THERAPY FOR THYROID CARCINOMA1,2,3 [J].
HAYNIE, TP ;
BEIERWALTES, WH .
JOURNAL OF NUCLEAR MEDICINE, 1963, 4 (02) :85-91
[27]   The effectiveness of multinodular large toxic goiter therapy using 131-I. [J].
Baczyk, M ;
Pisarek, M ;
Ziemnicka, K ;
Gut, P ;
Stankowiak-Kulpa, H ;
Gryczynska, M ;
Sowinski, J .
PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2004, :969-972
[28]   I-131 IN BREAST-MILK FOLLOWING THERAPY FOR THYROID-CARCINOMA [J].
ROBINSON, PS ;
BARKER, P ;
CAMPBELL, A ;
HENSON, P ;
SURVEYOR, I ;
YOUNG, PR .
JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (11) :1797-1801
[29]   SIALADENITIS FOLLOWING I-131 THERAPY FOR THYROID-CARCINOMA - CONCISE COMMUNICATION [J].
ALLWEISS, P ;
BRAUNSTEIN, GD ;
KATZ, A ;
WAXMAN, A .
JOURNAL OF NUCLEAR MEDICINE, 1984, 25 (07) :755-758
[30]   Influence of zinc on the biokinetics of I-131 and thyroid functions following lithium therapy [J].
Dhawan, D. ;
Nair, P. ;
Chadha, V. ;
Bhalla, P. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50